Barclays PLC Has $399,000 Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Barclays PLC raised its holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 292.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 57,599 shares of the company’s stock after purchasing an additional 42,926 shares during the quarter. Barclays PLC owned approximately 0.11% of Zevra Therapeutics worth $399,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its position in Zevra Therapeutics by 10.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 220,499 shares of the company’s stock worth $1,080,000 after buying an additional 21,231 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Zevra Therapeutics by 17.9% during the second quarter. Rhumbline Advisers now owns 56,874 shares of the company’s stock worth $279,000 after purchasing an additional 8,619 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after purchasing an additional 2,452 shares during the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of Zevra Therapeutics in the second quarter valued at approximately $474,000. Finally, SG Americas Securities LLC bought a new position in Zevra Therapeutics in the 3rd quarter worth approximately $105,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Stock Performance

Shares of ZVRA stock opened at $8.05 on Friday. The stock has a market cap of $429.71 million, a PE ratio of -4.09 and a beta of 2.01. The stock has a 50-day moving average of $8.70 and a 200-day moving average of $7.75. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. Zevra Therapeutics, Inc. has a one year low of $4.20 and a one year high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The firm had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period in the previous year, the company posted ($0.40) EPS. As a group, sell-side analysts expect that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have commented on ZVRA. Roth Mkm increased their price objective on Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Guggenheim started coverage on Zevra Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $20.00 price objective for the company. Cantor Fitzgerald initiated coverage on shares of Zevra Therapeutics in a research report on Wednesday, January 8th. They set an “overweight” rating and a $25.00 target price on the stock. JMP Securities assumed coverage on shares of Zevra Therapeutics in a research report on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price target for the company. Finally, Canaccord Genuity Group cut their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Zevra Therapeutics has an average rating of “Buy” and an average price target of $21.57.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.